Patel Naimish — SEC Form 4 filings
SEC reporting owner CIK 2021679. 12 Form 4 filings on record with FilingPulse; latest filed 2026-09-15.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-05-29 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,508 shares, $49,704 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 10,868 shares, $503,912 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: sale of 3,786 shares @ $55.62 ($210,577) in CRISPR Therapeutics AG, filed 2026-06-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | Chief Medical Officer | 11 | 1 leg · 1,508 sh · $49,704 | 3 legs · 10,868 sh · $503,912 | 16 |
| AgomAb Therapeutics NV (AGMB) | Director | 1 | — | — | 1 |
Form 4 filings — Patel Naimish
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | AgomAb Therapeutics NV (AGMB) | Grant/award (A): 56,328 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 10,000 · Sale (S): 3,786 @ $55.62 · Option exercise (M): 10,000 (derivative) | EDGAR |
| 2026-03-24 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 38,499 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 8,125 · Sale (S): 3,150 @ $48.26 · Option exercise (M): 8,125 (derivative) | EDGAR |
| 2026-01-27 | 4 | CRISPR Therapeutics AG (CRSP) | Purchase (P): 1,508 @ $32.96 | EDGAR |
| 2025-10-03 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | CRISPR Therapeutics AG (CRSP) | Option exercise (M): 10,000 · Sale (S): 3,932 @ $35.94 · Option exercise (M): 10,000 (derivative) | EDGAR |
| 2025-03-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 46,667 (derivative) @ $0 · Grant/award (A): 32,500 (derivative) @ $0 | EDGAR |
| 2024-10-18 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 18,333 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 85,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=2021679 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →